IMV finds 'breath­ing room' to look for deals or in­vest­ments, will not en­roll new pa­tients in PhI­Ib can­cer vac­cine tri­als

Can­cer vac­cine de­vel­op­er IMV is sus­pend­ing en­roll­ment in two Phase IIb tri­als as it be­gins a court-su­per­vised re­struc­tur­ing process to give it some breath­ing room …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER